权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Characterization and targeting of the epigenetic state underlying uveal melanoma liver metastasis

葡萄膜黑色素瘤肝转移表观遗传状态的表征和靶向

基本信息

批准号：
10675515
负责人：
JAMES WILLIAM HARBOUR
金额：
$ 63.84万
依托单位：
H. LEE MOFFITT CANCER CTR & RES INST
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-08-09 至 2026-07-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10675515
关键词：
ATAC-seq Adjuvant Therapy Adoption Alleles Animal Model Automobile Driving Binding Sites CRISPR screen Cells Chromatin Clinical Clinical Trials Data Data Set Dependence Development Diagnosis Disease Drug resistance Environment Epigenetic Process FGF2 gene Fostering GDF15 gene GNAQ gene Gene Expression Gene Expression Profiling Genes Genetic Genetic Predisposition to Disease Genetic Transcription Goals Grant Growth HDAC1 gene Hepatic Stellate Cell Histone Deacetylase IL8 gene Knowledge Liver MAP Kinase Gene MEK inhibition Maintenance Mediating Melanoma Cell Metastatic Neoplasm to the Liver Modeling Molecular Mus Mutation Neoplasm Metastasis Oncogenic Output Pathway interactions Patients Phenotype Program Sustainability Proteomics Risk Role Signal Induction Signal Pathway Signal Transduction Signaling Molecule Specimen Subgroup TP53 gene Testing Therapeutic Time Up-Regulation Uveal Melanoma Vascular Endothelial Growth Factors Xenograft Model angiogenesis combinatorial epigenomics high risk innovation jun Oncogene knock-down malignant neoplasm of eye melanocyte multiple omics mutant novel novel strategies novel therapeutic intervention prevent programs senescence small molecule inhibitor targeted treatment therapy resistant transcription factor treatment strategy tumor progression

项目摘要

Uveal melanoma (UM) is a highly aggressive and frequently fatal cancer of the eye. While only 2-4% of patients will have detectable metastases at diagnosis, up to 50% of patients later develop metastatic disease, overwhelmingly localized to the liver. Gene expression profiling separates UM to into two sub-groups, low risk Class 1 UM and high risk Class 2 UM. Almost all UMs harbor an initiating mutation in the Gαq signaling pathway, most commonly in GNAQ. Class 2 UMs harbor “progression mutations” in one of several genes that drive tumor progression, the most common being BAP1. Previous studies from our group identified biallelic inactivation of BAP1 as the strongest predictor of liver metastasis in UM. However, the cellular and molecular mechanisms underlying liver metastasis in UM remain undetermined. This gap in our knowledge limits our ability to develop effective adjuvant treatment for high risk patients and systemic treatments for disseminated disease. Gαq signaling activates the MAPK pathway in UM cells, and our preliminary single cell data show that Gαq- mutant UMs are enriched for FOS/JUN transcriptional states. Loss of BAP1 function was associated with escape from senescence, and a de-differentiated phenotype in UM cells that allowed their interaction with hepatic stellate cells, leading to progression of liver metastases and drug resistance. The dedifferentiated state of UM cells was specifically dependent on HDAC1, with HDAC inhibition restoring the differentiated state of UM cells, and increasing the efficacy of MEK inhibition in UM liver metastasis models. The overarching goal of this grant is to define the mechanism by which mutant Gαq and BAP1 loss co-operate to drive UM liver metastasis development. In Aim 1 we will define how BAP1 loss alters the signaling, transcriptional and epigenetic state of Gαq-mutant UM cells to allow senescence to be overcome. In Aim 2, we will address how the cellular state of Gαq-mutant/BAP1-loss UM activates hepatic stellate cells to generate a pro-survival niche in the liver through increased angiogenesis and upregulation of MAPK signaling. In Aim 3, we will explore the HDAC1 dependency of the Gαq-BAP1 loss UM cell state and will validate hits from recent CRISPR screens to identify novel therapeutic approaches to treat UM liver metastases, that we will validate in animal models. At completion of this study, we expect to have defined new approaches to prevent and treat UM liver metastases, that we will explore in clinical trials.

葡萄膜黑色素瘤（UM）是一种高度侵袭性和经常致命的眼睛癌症。只有2-4%的患者在诊断时将具有可检测的转移，高达50%的患者后来发展为转移性疾病，主要集中在肝脏基因表达谱将UM分为两个亚组，低风险 1类UM和高风险2类UM。几乎所有的UM都在Gαq信号通路中存在起始突变途径，最常见于GNAQ。2类UM在几个基因中的一个中携带“进展突变”，驱动肿瘤进展，最常见的是BAP 1。我们小组以前的研究确定了双等位基因 BAP 1的失活是UM肝转移的最强预测因子。然而，细胞和分子 UM肝转移的潜在机制仍不确定。我们知识上的差距限制了我们有能力为高危患者开发有效的辅助治疗，并为播散性肿瘤患者开发系统性治疗。疾病 Gαq信号激活UM细胞中的MAPK通路，我们初步的单细胞数据显示Gαq- 突变体UM富含FOS/JUN转录状态。BAP 1功能丧失与以下因素相关：逃避衰老，以及UM细胞中的去分化表型，其允许它们与肝星状细胞，导致肝转移和耐药性的进展。去分化状态的UM细胞特异性依赖于HDAC 1，HDAC抑制恢复了UM细胞的分化状态。 UM细胞，并增加UM肝转移模型中MEK抑制的功效。的首要目标该基金的目的是确定突变型Gαq和BAP 1缺失协同驱动UM肝脏的机制转移发展在目标1中，我们将定义BAP 1丢失如何改变信号传导、转录和转录。 Gα q突变UM细胞的表观遗传状态，以允许克服衰老。在目标2中，我们将讨论如何 Gα q突变体/BAP 1缺失UM的细胞状态激活肝星状细胞产生促存活小生境在肝脏中通过增加血管生成和MAPK信号传导的上调。在目标3中，我们将探讨 Gα q-BAP 1损失UM细胞状态的HDAC 1依赖性，并将验证最近CRISPR筛选的命中，确定新的治疗方法来治疗UM肝转移，我们将在动物模型中验证。在完成这项研究后，我们期望确定预防和治疗UM肝转移的新方法，我们将在临床试验中探索。

项目成果

期刊论文数量（2）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

HDAC11 activity contributes to MEK inhibitor escape in uveal melanoma.

DOI：
10.1038/s41417-022-00452-7
发表时间：
2022-12
期刊：
CANCER GENE THERAPY
影响因子：
6.4
作者：
Sriramareddy, Sathya Neelature;Faiao-Flores, Fernanda;Emmons, Michael F.;Saha, Biswarup;Chellappan, Srikumar;Wyatt, Clayton;Smalley, Inna;Licht, Jonathan D.;Durante, Michael A.;Harbour, J. William;Smalley, Keiran S. M.
通讯作者：
Smalley, Keiran S. M.